- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 14/56 - IFN-alpha
Patent holdings for IPC class C07K 14/56
Total number of patents in this class: 619
10-year publication summary
|
38
|
34
|
39
|
55
|
38
|
32
|
42
|
40
|
24
|
21
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Vib VZW | 889 |
40 |
| Universiteit Gent | 1371 |
37 |
| Orionis Biosciences BV | 76 |
36 |
| Orionis Biosciences Inc. | 106 |
28 |
| Centre National de La Recherche Scientifique | 10895 |
22 |
| Modernatx, Inc. | 1274 |
22 |
| Centre hospitalier Regional universitaire de Montpellier | 31 |
15 |
| CytomX Therapeutics, Inc. | 228 |
13 |
| Teva Pharmaceuticals Australia Pty Ltd | 29 |
12 |
| Universite de Montpellier | 1031 |
12 |
| PharmaEssentia Corp. | 100 |
11 |
| ILC Therapeutics Ltd | 24 |
10 |
| Glaxo Group Limited | 4364 |
9 |
| The Regents of the University of California | 20587 |
9 |
| Rutgers, The State University of New Jersey | 1956 |
8 |
| Ubiprotein, Corp. | 12 |
8 |
| President and Fellows of Harvard College | 6055 |
6 |
| Biosteed Gene Expression Tech. Co., Ltd. | 12 |
6 |
| IBC Pharmaceuticals, Inc. | 56 |
6 |
| ImmunGene Inc. | 12 |
6 |
| Other owners | 303 |